MindBio Therapeutics Corp., together with its subsidiaries, research, develops, and tests psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for debilitating health conditions, such as depression, anxiety, PTSD, and chronic pain. MindBio Therapeutics Corp. was incorporated in 2021 and is headquartered in Vancouver, Canada.